In t-MDS patients, no IDH2 mutations were detected and about 3.5% of IDH1 mutations; in t-AML, a frequency of IDH1 and IDH2 mutations were comparable to that observed in de novo-AML [81]. This evidence concerns the gene IDH1 and acute myeloid leukemia.